FY25 consensus $119/5M. Cites delayed Etorel rollout and government procurement-related uncertainty.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Gyre Therapeutics reports Q3 EPS 3c, consensus (2c)
- Buy Rating for Gyre Therapeutics Driven by Phase 3 Trial Progress and Strategic Asset Valuation
- Gyre Therapeutics completes enrollment in Phase 3 trial of Pirfenidone capsules
- Gyre Therapeutics initiated with a Buy at Jefferies
- Gyre Therapeutics Announces Positive Phase 3 Results